Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy, depending on the level of PD-L1 expression. Regimens that use dual checkpoint blockade are also available, such as Opdivo + Yervoy (Bristol Myers Squibb and Ono Pharmaceutical), with or without platinum-based chemotherapy, and Imfinzi + Imjudo (AstraZeneca) plus platinum-based chemotherapy. Second- and later-line treatment options are limited and largely depend on the regimen used in the prior lines. Despite these treatment options, there is a need for more effective and diverse treatments for patients with NSCLC without driver mutations.
Questions answered
- Which attributes most influence physicians’ decisions for metastatic NSCLC without driver mutations?
- How do key current therapies, such as Keytruda, perform on key treatment drivers and goals for this patient population?
- What are the prevailing areas of unmet need and hidden opportunities in the treatment of this patient population?
- What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a hypothetical new first-line treatment for metastatic NSCLC without driver mutations?
Product description
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Markets covered: United States, France, Germany, United Kingdom.
Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in February 2026.
Key companies: Merck & Co., Bristol Myers Squibb, Ono Pharmaceutical, AstraZeneca, Roche / Genentech, Regeneron Pharmaceuticals.
Key drugs: Keytruda, Opdivo, Yervoy, Tecentriq, Imfizi, Libtayo.
Key feature: Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
